Hiking the price of a drug before generics appear is a long-enshrined practice, a situation that applies to most of the products singled out by Icer.
Megadeals flattered the biopharma M&A scene in the first half of 2019, but the numbers took a nose dive in the third-quarter.
Non-US big biopharma stocks led the way in the third quarter, suggesting that those looking for investment gains would do best to search further afield.
An analysis of EvaluatePharma data shows that, in a Bristol-Myers Squelgene world, all big pharmas are increasing their reliance on external projects.
Last week's pivotal trial success could give Celgene a second AML drug, setting up a battle against Roche's Venclexta and idasanutlin.
Planned divestment of Celgene’s psoriasis blockbuster means instant cashback for Bristol, a result the markets see as a win-win-win.
Nucana’s recent setback with Acelarin adds to the long list of pancreatic cancer failures, and a look at the late-stage pipeline shows little concrete progress.
Patent expiries and challenges have done little to halt the sales of some of the industry's biggest products.